drugset / Trial / NCT06970496
A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
Phase 1
Not yet recruiting
48 enrolled
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the safety、tolerability and preliminary efficacy of B019 in subjects with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Timeline
- Start
- 2026-08-31
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | B019 | Unknown | 2e+06 cells/kg | Intravenous |
| Subject | B019 | Unknown | 8e+06 cells/kg | Intravenous |